Literature DB >> 28397105

Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer.

Ayumu Kusaka1, Shingo Hatakeyama2, Shogo Hosogoe1, Itsuto Hamano1, Hiromichi Iwamura1, Naoki Fujita1, Ken Fukushi1, Takuma Narita1, Hayato Yamamoto1, Yuki Tobisawa1, Tohru Yoneyama3, Takahiro Yoneyama1, Yasuhiro Hashimoto3, Takuya Koie1, Hiroyuki Ito4, Kazuaki Yoshikawa5, Toshiaki Kawaguchi6, Chikara Ohyama1,3.   

Abstract

The prognostic benefit of oncological follow-up to detect asymptomatic recurrence after radical cystectomy (RC) remains unclear. We aimed to assess whether routine follow-up to detect asymptomatic recurrence after RC improves patient survival. We retrospectively analyzed 581 RC cases for muscle-invasive bladder cancer at four hospitals between May 1996 and February 2017. All patients had regular follow-up examinations with urine cytology, blood biochemical tests, and computed tomography after RC. We investigated the first site and date of tumor recurrence. Overall survival in patients with recurrence stratified by the mode of recurrence (asymptomatic group vs. symptomatic group) was estimated using the Kaplan-Meier method with the log-rank test. Cox proportional hazards regression analysis via inverse probability of treatment weighting (IPTW) was used to evaluate the impact of the mode of diagnosing recurrence on survival. Of the 581 patients, 175 experienced relapse. Among those, 12 without adequate data were excluded. Of the remaining 163 patients, 76 (47%) were asymptomatic and 87 (53%) were symptomatic at the time of diagnosis. The most common recurrence site and symptom were lymph nodes (47%) and pain (53%), respectively. Time of overall survival after RC and from recurrence to death was significantly longer in the asymptomatic group than in the symptomatic group. A multivariate Cox regression analysis using IPTW showed that in the patients with symptomatic recurrence was an independent risk factor for overall survival after RC and survival from recurrence to death. Routine oncological follow-up for detection of asymptomatic recurrence contributes to a better prognosis after RC.

Entities:  

Keywords:  Asymptomatic; Radical cystectomy; Recurrence; Survival; Symptomatic

Mesh:

Year:  2017        PMID: 28397105     DOI: 10.1007/s12032-017-0955-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Bladder substitution after pelvic evisceration.

Authors:  E M BRICKER
Journal:  Surg Clin North Am       Date:  1950-10       Impact factor: 2.741

2.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

3.  Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach.

Authors:  Suzanne B Stewart-Merrill; Stephen A Boorjian; Robert Houston Thompson; Sarah P Psutka; John C Cheville; Prabin Thapa; Eric J Bergstrahl; Matthew K Tollefson; Igor Frank
Journal:  Urol Oncol       Date:  2015-05-29       Impact factor: 3.498

4.  Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: clinical and oncological outcomes at a single institution.

Authors:  T Koie; C Ohyama; H Yamamoto; S Hatakeyama; S Kudoh; T Yoneyama; Y Hashimoto; N Kamimura
Journal:  Eur J Surg Oncol       Date:  2012-08-03       Impact factor: 4.424

5.  Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival.

Authors:  Stephen A Boorjian; Matthew K Tollefson; John C Cheville; Brian A Costello; Prabin Thapa; Igor Frank
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

6.  Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?

Authors:  Gianluca Giannarini; Thomas M Kessler; Harriet C Thoeny; Daniel P Nguyen; Claudia Meissner; Urs E Studer
Journal:  Eur Urol       Date:  2010-06-04       Impact factor: 20.096

Review 7.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

8.  Uterus-, fallopian tube-, ovary-, and vagina-sparing cystectomy followed by U-shaped ileal neobladder construction for female bladder cancer patients: oncological and functional outcomes.

Authors:  Takuya Koie; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Noritaka Kamimura; Chikara Ohyama
Journal:  Urology       Date:  2009-12-06       Impact factor: 2.649

9.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

10.  Cost of patient follow-up after potentially curative colorectal cancer treatment.

Authors:  K S Virgo; A M Vernava; W E Longo; L W McKirgan; F E Johnson
Journal:  JAMA       Date:  1995-06-21       Impact factor: 56.272

View more
  10 in total

1.  Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Authors:  Koichi Kido; Shingo Hatakeyama; Naoki Fujita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ikuya Iwabuchi; Masaru Ogasawara; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2018-02-12       Impact factor: 3.402

2.  Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer.

Authors:  Chelsea K Osterman; Jaber Alanzi; James D Lewis; Elizabeth L Kaufman; Vivek Narayan; Ben Boursi; Ravy K Vajravelu; Frank I Scott; S Bruce Malkowicz; Ronac Mamtani
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

3.  Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.

Authors:  Sakae Konishi; Shingo Hatakeyama; Toshiaki Tanaka; Yoshinori Ikehata; Toshikazu Tanaka; Naoki Fujita; Yusuke Ishibashi; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Naoya Masumori; Hiroshi Kitamura; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-11-24       Impact factor: 3.064

4.  Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.

Authors:  Hirotaka Horiguchi; Takahiro Yoneyama; Shingo Hatakeyama; Noriko Tokui; Tendo Sato; Naoki Fujita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Kazuaki Yoshikawa; Satoshi Narita; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-02-26       Impact factor: 3.064

5.  Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma.

Authors:  Sappaya Suppanuntaroek; Shingo Hatakeyama; Naoki Fujita; Yuka Kubota; Yuichiro Suzuki; Teppei Okamoto; Yuki Tobisawa; Tohru Yoneyama; Hayato Yamamoto; Kazuyuki Mori; Atsushi Imai; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2019-10-26       Impact factor: 3.402

6.  Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma.

Authors:  Hirotaka Horiguchi; Shingo Hatakeyama; Go Anan; Yuka Kubota; Hirotake Kodama; Masaki Momota; Koichi Kido; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2018-01-04

7.  Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Authors:  Masaki Momota; Shingo Hatakeyama; Hayato Yamamoto; Hiromichi Iwamura; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ikuya Iwabuchi; Masaru Ogasawara; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2018-05-01

8.  Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.

Authors:  Itsuto Hamano; Shingo Hatakeyama; Hiromichi Iwamurau; Naoki Fujita; Ken Fukushi; Takuma Narita; Kazuhisa Hagiwara; Ayumu Kusaka; Shogo Hosogoe; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-05-29

Review 9.  Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma.

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Makoto Sato; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

10.  Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.

Authors:  Go Anan; Shingo Hatakeyama; Naoki Fujita; Hiromichi Iwamura; Toshikazu Tanaka; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-09-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.